Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Status:
Completed
Trial end date:
2018-04-26
Target enrollment:
Participant gender:
Summary
This Phase Ib study will identify the Maximum Tolerated Dose (MTD) of AZD1775 monotherapy
when administered orally once daily (QD) or two times per day (BID) on Days 1 to 5 followed
by 9 days of rest in 14-day cycles, or QD on a 5/2 dosing schedule (5 days on, followed by 2
days rest) in 21-day cycles in patients with locally advanced or metastatic solid tumours.
Alternative treatment schedules may be explored if preliminary data suggest these would be
more appropriate.
The effect of food on single dose PK of AZD1775 will be assessed in 12 patients. In this
sub-study, patients will receive a single oral dose of AZD1775 with 240 mL of water, once in
the fasted state and once following a high-fat meal.